Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Docetaxel With or Without a Phytochemical in Treating Patients With Breast Cancer

This study is currently recruiting participants. (see Contacts and Locations)
Verified July 2016 by Centre Jean Perrin
Sponsor:
Information provided by (Responsible Party):
Centre Jean Perrin
ClinicalTrials.gov Identifier:
NCT00852332
First received: February 26, 2009
Last updated: July 28, 2016
Last verified: July 2016
  Purpose

RATIONALE: Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Dietary supplements, such as phytochemicals, may stop or delay the development of breast cancer. It is not yet known whether giving docetaxel together with a phytochemical is more effective than giving docetaxel alone in treating patients with breast cancer.

PURPOSE: This randomized phase II trial is studying how well giving docetaxel together with a phytochemical works compared with giving docetaxel alone as first- or second-line therapy in treating patients with breast cancer.


Condition Intervention Phase
Breast Cancer
Dietary Supplement: Curcumin
Drug: Taxotere
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: An Open-label, Randomised, Phase II Study of Docetaxel in Combination With a Dietary Phytonutrient in First or Second Line Treatment for Patients With HER2 Negative Locally Advanced or Metastatic Breast Cancer, or Loco-regional Recurrence Not Amenable to Treatment by Surgery or Radiotherapy.

Resource links provided by NLM:


Further study details as provided by Centre Jean Perrin:

Primary Outcome Measures:
  • Response rate as assessed by RECIST criteria [ Time Frame: From the date of randomization until the end of the treatment, assessed up to 21 weeks ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Overall clinical benefit rate as assessed by RECIST criteria [ Time Frame: From the date of randomization until the end of the treatment, assessed up to 21 weeks ] [ Designated as safety issue: No ]
  • Time to progression as assessed by RECIST criteria [ Time Frame: From date of randomization until the date of first documented progression or date of death from any cause, assessed up to 21 weeks ] [ Designated as safety issue: No ]
  • Overall survival as assessed by RECIST criteria [ Time Frame: From the date of randomization until the date of death from any cause ] [ Designated as safety issue: No ]
    Evaluate overall survival (between inclusion and death whatever the cause)

  • Safety as assessed by NCI CTCAE v3.0 [ Time Frame: From the date of randomization until the end of the treatment, assessed up to 21 weeks ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 100
Study Start Date: August 2009
Estimated Primary Completion Date: January 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Curcumine
With curcumin capsules
Dietary Supplement: Curcumin Drug: Taxotere
Active Comparator: Drug taxotere only
Without curcumin
Drug: Taxotere

Detailed Description:

OBJECTIVES:

Primary

  • To compare the response rate in HER2-negative patients with locally advanced or metastatic breast cancer or locoregional breast cancer recurrence treated with docetaxel and a dietary phytochemical vs docetaxel alone.

Secondary

  • To compare the overall clinical benefit rate (i.e., objective response plus stable disease) in patients treated with these regimens.
  • To compare time to progression in patients treated with these regimens.
  • To compare overall survival of patients treated with these regimens.
  • To assess biomarkers of response in blood samples from patients treated with these regimens.

OUTLINE: This is a multicenter study. Patients are stratified according to recruitment center and line of chemotherapy (first vs second line of docetaxel). Patients are randomized to 1 of 2 treatment arms.

  • Arm I: Patients receive docetaxel IV over 1 hour on day 1. Treatment repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
  • Arm II: Patients receive docetaxel as in arm I. Patients also receive an oral dietary phytochemical twice on day 1. Treatment repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.

After completion of study therapy, patients are followed periodically.

  Eligibility

Ages Eligible for Study:   18 Years to 120 Years   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

DISEASE CHARACTERISTICS:

  • Histologically or cytologically confirmed adenocarcinoma of the breast, meeting 1 of the following criteria:

    • Locally advanced disease
    • Documented metastatic disease without overexpression of Her2/neu

      • Must have received prior anthracycline-containing regimen as neoadjuvant, adjuvant, or first-line chemotherapy for metastatic breast cancer
    • Loco-regional recurrence not amenable to treatment by surgery or radiotherapy
  • At least one measurable lesion according to RECIST criteria

    • No bone lesion only disease
  • Must be a candidate for taxane-based chemotherapy
  • HER2-negative disease
  • No symptomatic brain metastases
  • Hormone receptor status not specified

PATIENT CHARACTERISTICS:

  • Menopausal status not specified
  • WHO performance status 0-2
  • Life expectancy ≥ 3 months
  • ANC ≥ 2,000/mm³
  • Platelet count ≥ 100,000/mm³
  • Hemoglobin ≥ 10 g/dL
  • Serum creatinine < 140 µmol/L OR creatinine clearance > 60 mL/min
  • Total bilirubin ≤ upper limit of normal (ULN)
  • AST and ALT ≤ 1.5 times ULN
  • Alkaline phosphatase ≤ 2.5 times ULN
  • Not pregnant or nursing
  • Fertile patients must use effective contraception
  • No history of significant neurologic (i.e., peripheral neuropathy ≥ grade 2) or psychiatric disorders, including psychotic disorders, dementia, or seizures that would prohibit the understanding, observance, and giving of informed consent
  • No other prior or concomitant malignancies except adequately treated carcinoma in situ of the cervix uteri, basal cell or squamous cell carcinoma of the skin, or other cancer curatively treated with surgery and/or radiotherapy
  • No concurrent severe and/or uncontrolled co-morbid medical condition
  • No medically unstable patients
  • No uncontrolled infection
  • No autoimmune disease and/or chronic active inflammation
  • No psychological, familial, social, or geographical reasons that would make clinical follow-up impossible
  • No malabsorption syndrome or disease significantly affecting gastrointestinal function
  • No dysphagia ≥ grade 2
  • No history of hypersensitivity to taxanes or known excipients, including polysorbate 80

PRIOR CONCURRENT THERAPY:

  • See Disease Characteristics
  • No prior major resection of the stomach or proximal small bowel
  • Prior hormonal therapy as adjuvant treatment and/or treatment of metastatic disease allowed provided that the patient has progressive disease at study entry

    • Hormonal treatment must be discontinued prior to study entry
  • No more than 1 prior chemotherapy regimen for metastatic disease
  • More than 30 days since prior investigational drug
  • More than 3 weeks since prior NSAIDs or COX_2 inhibitors
  • No other concurrent anticancer therapy
  • No other concurrent dietary phytonutrients
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00852332

Locations
France
Centre Jean Perrin Recruiting
Clermont-Ferrand, France, 63011
Contact: Philippe Chollet, MD, PhD    33-4-7327-8198    philippe.chollet@cjp.fr   
Sponsors and Collaborators
Centre Jean Perrin
Investigators
Principal Investigator: Philippe Chollet, MD, PhD Centre Jean Perrin
  More Information

Responsible Party: Centre Jean Perrin
ClinicalTrials.gov Identifier: NCT00852332     History of Changes
Other Study ID Numbers: CDR0000635901  JEANP-CURRYTAX  INCA-RECF0908  EUDRACT-2008-003930-19 
Study First Received: February 26, 2009
Last Updated: July 28, 2016
Health Authority: FRANCE : ANSM - Agence Nationale de Sécurité du Médicament

Keywords provided by Centre Jean Perrin:
male breast cancer
stage IIIB breast cancer
stage IIIC breast cancer
stage IV breast cancer
recurrent breast cancer
stage IIIA breast cancer
HER2-negative breast cancer

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases
Docetaxel
Curcumin
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents
Enzyme Inhibitors

ClinicalTrials.gov processed this record on December 02, 2016